aiSLE DX -Advanced Blood Test Program
Immunological insights for proactive lupus care; Get started today with aiSLE DX Flare Risk Index, a new blood test that identifies a SLE patient`s future risk of a lupus flare.
Anticipate the onset of lupus flares with a blood test.
aiSLE™ DX Flare Risk Index is an advanced blood test that can help inform the risk of a systemic lupus erythematosus-related flare within the next 12 weeks.
The aiSLE™ DX Flare Risk Index was initially developed from studies of SLE patients presenting for treatment at several lupus centers of excellence in the United States. People of diverse racial and ethnic backgrounds participated in the studies including European Americans, African Americans, and Native Americans. These studies indicated the ability of the assay to potentially provide a robust, predictive gauge of impending disease flare with high degrees of accuracy.
DEVELOPING AISLE™ DX
The aiSLE™ DX tests were developed from studies of SLE patients presenting for treatment at several lupus Centers of Excellence in the United States. Studies were completed in both European and African Americans SLE patients, and indicated the ability of the assay to potentially provide a robust, predictive gauge of impending disease flare with high degrees of accuracy. Patients in each study with confirmed disease flares were matched after a baseline pre-flare assessment, with SLE patients without impending flare (non-flare), and healthy controls.
HOW IT WORKS
A well-defined set of immune modulatory soluble mediators, including cytokines, chemokines, and soluble receptors shown to be altered in plasma prior to disease flare in SLE patients, are examined in this test Although any one individual biomarker might not be universally correlated with the development of flares, the overall balance between inflammatory and regulatory mediators has demonstrated the potential to predict impending flares in SLE patients.
A number of soluble immune mediators were assessed in these SLE patients for baseline and follow up plasma levels. Subsequent work has refined and narrowed the number of immune mediators that are included in the aiSLE DX Flare Risk Index. An algorithm using weighted levels of a panel of immune mediators is used to calculate a Flare Risk Index (FRI), which assigns an individual risk score indicative of the patient’s risk of an impending flare within the next 12 weeks.